Shanghai MicroPort Medical (Group) Co., Ltd.
24
0
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.5% vs industry average
8%
2 trials in Phase 3/4
71%
5 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Firehawk Rapamycin Target Eluting Coronary Stent North American Trial
Role: lead
TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
Role: lead
Compare Sirolimus Coated Balloon Catheter With Paclitaxel Coated Balloon Catheter in De Novo Coronary Bifurcated Lesions
Role: lead
A First-in-Man Study of the Firesorb BVS (FUTURE-I)
Role: lead
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
Role: lead
Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )
Role: lead
Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
Role: lead
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke
Role: lead
Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease
Role: lead
A Trial of DCB vs DES in the Treatment of de Novo Large Diameter Coronary Atherosclerotic Stenosis(LARGE ONE)
Role: lead
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
Role: lead
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
Role: lead
Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff Tear
Role: lead
Trial for MicroPort's DCB
Role: lead
OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation
Role: lead
Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)
Role: lead
The First-In-Man Pilot Study of Firehawk
Role: lead
Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)
Role: lead
Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
Role: lead
Trial for MicroPort's Firesorb BVS: FUTURE-III
Role: lead